- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07387198
Thérapie (Tx) néoadjuvante du carcinome à cellules de Merkel avec l'inhibiteur PD-1 Cemiplimab (NeoMatryx)
Thérapie néoadjuvante du carcinome à cellules de Merkel (Tx) avec l'inhibiteur PD-1 Cemiplimab - Une étude randomisée, en double aveugle, contrôlée par placebo, de phase II non comparative
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Michelle Tez
- E-mail: tez.michelle@ikf-khnw.de
Sauvegarde des contacts de l'étude
- Nom: Ralf Gutzmer, Prof. Dr. med.
- E-mail: Ralf.Gutzmer@Muehlenkreiskliniken.de
Lieux d'étude
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Allemagne, 69120
- Recrutement
- Nationales Centrum für Tumorerkrankungen
-
Contact:
- Jessica Hassel, Prof. Dr.
-
Mannheim, Baden-Wurttemberg, Allemagne, 68161
- Recrutement
- Universitätsklinikum Mannheim
-
Contact:
- Jochen Utikal, Prof. Dr.
-
Tübingen, Baden-Wurttemberg, Allemagne, 72076
- Recrutement
- Universitätsklinikum Tübingen
-
Contact:
- Ulrike Leiter-Stöppke, Prof. Dr.
-
-
Bavaria
-
Regensburg, Bavaria, Allemagne, 93053
- Recrutement
- Universitätsklinikum Regensburg
-
Contact:
- Sebastian Haferkamp, Prof. Dr.
-
Würzburg, Bavaria, Allemagne, 97080
- Recrutement
- Universitätsklinikum Würzburg
-
Contact:
- Anja Gieserich, Dr.
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Allemagne, 20246
- Recrutement
- Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Christoffer Gebhardt, Prof. Dr.
-
-
Hesse
-
Frankfurt am Main, Hesse, Allemagne, 60590
- Recrutement
- Universitätsklinikum Frankfurt
-
Contact:
- Bastian Schilling, Prof. Dr.
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Allemagne, 33647
- Recrutement
- Klinikum Bielefeld
-
Contact:
- Selma Ugurel, Prof. Dr.
-
Essen, North Rhine-Westphalia, Allemagne, 45147
- Recrutement
- Universitätsklinikum Essen
-
Contact:
- Dirk Schadendorf, Prof. Dr.
-
Minden, North Rhine-Westphalia, Allemagne, 32429
- Pas encore de recrutement
- Johannes Wesling Klinikum Minden
-
Contact:
- Ralf Gutzmer, Prof. Dr.
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Allemagne, 55131
- Recrutement
- Universitätsmedizin Mainz
-
Contact:
- Stefan Grabbe, Prof. Dr.
-
-
Thuringia
-
Erfurt, Thuringia, Allemagne, 99089
- Recrutement
- Helios Klinikum Erfurt
-
Contact:
- Rudolph Herbst, Prof. Dr.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria
-
Patient has signed informed written consent.
-
Patients is 18 years and older at time of signing of written informed consent
-
Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.
-
Patient has ECOG performance status 0-2.
-
Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.
- Absolute number of neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
- AST (SGOT) and ALT (SGPT) ≤ 3x ULN
- AP ≤ 2.5x ULN
- Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
-
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
-
Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
-
Patient has prior sentinel lymph node removal for the current MCC.
-
Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)
-
Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
-
Patient had prior organ transplantation including allogenic stem-cell transplantation.
-
Patient receives immunosuppressive concomitant medication, EXCEPT for the following:
i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).
ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
-
Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has active autoimmune or inflammatory disorders.
-
Patient has history of interstitial lung disease.
-
Patient has active infection requiring systemic therapy.
-
Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.
NOTE: Patients are eligible if:
- Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
- Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
- Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
-
Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
-
Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
-
Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
-
Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
-
Patient is legally incapacitated or has limited legal capacity
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm A (Cemiplimab)
2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy |
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Autres noms:
|
|
Comparateur placebo: Arm B (placebo)
2 cycles of placebo followed by sentinel lymph node biopsy |
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Nodal micrometastases-free rate
Délai: up to 36 months
|
rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
up to 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recurrence-free survival
Délai: up to 66 months
|
time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death |
up to 66 months
|
|
Time to recurrence
Délai: up to 66 months
|
defined as time from randomization until date of first MCC recurrence |
up to 66 months
|
|
Overall survival
Délai: up to 66 months
|
time from randomization until date of death from any cause |
up to 66 months
|
|
Quality of life using FCRI-SF questionnaire
Délai: up to 66 months
|
Quality of life determined using the FCRI-SF questionnaire |
up to 66 months
|
|
Safety (AEs and SAEs)
Délai: up to 66 months
|
incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
up to 66 months
|
|
Disease specific survival
Délai: up to 66 months
|
time from randomization until date of MCC-related death |
up to 66 months
|
|
Quality of life using the mFACT-M questionnaire
Délai: up to 66 months
|
Quality of life determined using the mFACT-M questionnaire |
up to 66 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Délai: up to 66 months
|
Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS |
up to 66 months
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Directeur d'études: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
- Chercheur principal: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
- Chercheur principal: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Infections
- Maladies virales
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Infections par le virus de l'ADN
- Maladies de la peau
- Carcinome
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroendocrines
- Infections virales tumorales
- Infections à polyomavirus
- Carcinome neuroendocrinien
- Maladies de la peau et du tissu conjonctif
- Tumeurs cutanées
- Carcinome, cellule de Merkel
- cémiplimab
Autres numéros d'identification d'étude
- NeoMatryx
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .